Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ)

CNY 8.97

(0.56%)

Market Cap (In CNY)

14.65 Billion

Revenue (In CNY)

2.84 Billion

Net Income (In CNY)

847.22 Million

Avg. Volume

10.32 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
7.41-11.77
PE
-
EPS
-
Beta Value
0.571
ISIN
CNE100000GY2
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Lihua Song
Employee Count
-
Website
https://www.ankebio.com
Ipo Date
2009-10-30
Details
Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers recombinant human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It also provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, sperm DNA fragmentation staining, and leptin and immunohistochemical diagnostic kits. In addition, the company offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care and anti-aging products; and synthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, it provides autosomal, sex chromosome, autosomal and sex chromosome combination, and other kits, as well as paternity testing set packages; tumor biological immunotherapy products; and DNA testing professional services. The company was founded in 2000 and is based in Hefei, China.